» Articles » PMID: 38282078

Differentiating IDH-mutant Astrocytomas and 1p19q-codeleted Oligodendrogliomas Using DSC-PWI: High Performance Through Cerebral Blood Volume and Percentage of Signal Recovery Percentiles

Abstract

Objective: Presurgical differentiation between astrocytomas and oligodendrogliomas remains an unresolved challenge in neuro-oncology. This research aims to provide a comprehensive understanding of each tumor's DSC-PWI signatures, evaluate the discriminative capacity of cerebral blood volume (CBV) and percentage of signal recovery (PSR) percentile values, and explore the synergy of CBV and PSR combination for pre-surgical differentiation.

Methods: Patients diagnosed with grade 2 and 3 IDH-mutant astrocytomas and IDH-mutant 1p19q-codeleted oligodendrogliomas were retrospectively retrieved (2010-2022). 3D segmentations of each tumor were conducted, and voxel-level CBV and PSR were extracted to compute mean, minimum, maximum, and percentile values. Statistical comparisons were performed using the Mann-Whitney U test and the area under the receiver operating characteristic curve (AUC-ROC). Lastly, the five most discriminative variables were combined for classification with internal cross-validation.

Results: The study enrolled 52 patients (mean age 45-year-old, 28 men): 28 astrocytomas and 24 oligodendrogliomas. Oligodendrogliomas exhibited higher CBV and lower PSR than astrocytomas across all metrics (e.g., mean CBV = 2.05 and 1.55, PSR = 0.68 and 0.81 respectively). The highest AUC-ROCs and the smallest p values originated from CBV and PSR percentiles (e.g., PSRp70 AUC-ROC = 0.84 and p value = 0.0005, CBVp75 AUC-ROC = 0.8 and p value = 0.0006). The mean, minimum, and maximum values yielded lower results. Combining the best five variables (PSRp65, CBVp70, PSRp60, CBVp75, and PSRp40) achieved a mean AUC-ROC of 0.87 for differentiation.

Conclusions: Oligodendrogliomas exhibit higher CBV and lower PSR than astrocytomas, traits that are emphasized when considering percentiles rather than mean or extreme values. The combination of CBV and PSR percentiles results in promising classification outcomes.

Clinical Relevance Statement: The combination of histogram-derived percentile values of cerebral blood volume and percentage of signal recovery from DSC-PWI enhances the presurgical differentiation between astrocytomas and oligodendrogliomas, suggesting that incorporating these metrics into clinical practice could be beneficial.

Key Points: • The unsupervised selection of percentile values for cerebral blood volume and percentage of signal recovery enhances presurgical differentiation of astrocytomas and oligodendrogliomas. • Oligodendrogliomas exhibit higher cerebral blood volume and lower percentage of signal recovery than astrocytomas. • Cerebral blood volume and percentage of signal recovery combined provide a broader perspective on tumor vasculature and yield promising results for this preoperative classification.

Citing Articles

Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas.

Zhang X, Lu J, Liu X, Sun P, Qin Q, Xiang Z Front Oncol. 2025; 14:1507335.

PMID: 39759149 PMC: 11695364. DOI: 10.3389/fonc.2024.1507335.


Comparison of normalized cerebral blood flow between different post-processing methods of dynamic susceptibility contrast perfusion-weighted imaging and arterial spin labeling in gliomas with different grading.

Wang C, Liu F, Zhang L, Song Y, Pan Z, Li G Quant Imaging Med Surg. 2024; 14(12):8720-8733.

PMID: 39698595 PMC: 11652009. DOI: 10.21037/qims-24-1076.


"Synthetic" DSC Perfusion MRI with Adjustable Acquisition Parameters in Brain Tumors Using Dynamic Spin-and-Gradient-Echo Echoplanar Imaging.

Sanvito F, Yao J, Cho N, Raymond C, Telesca D, Pope W AJNR Am J Neuroradiol. 2024; 46(2):311-320.

PMID: 39242197 PMC: 11878977. DOI: 10.3174/ajnr.A8475.

References
1.
Mitchell D, Shireman J, Dey M . Surgical Neuro-Oncology: Management of Glioma. Neurol Clin. 2022; 40(2):437-453. PMC: 9048103. DOI: 10.1016/j.ncl.2021.11.003. View

2.
Balana C, Castaner S, Carrato C, Moran T, Lopez-Paradis A, Domenech M . Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics. Front Neurol. 2022; 13:865171. PMC: 9177999. DOI: 10.3389/fneur.2022.865171. View

3.
Vagvala S, Guenette J, Jaimes C, Huang R . Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics. Cancer Imaging. 2022; 22(1):19. PMC: 9014574. DOI: 10.1186/s40644-022-00455-5. View

4.
Patel S, Batchala P, Mrachek E, Lopes M, Schiff D, Fadul C . MRI and CT Identify Isocitrate Dehydrogenase -Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization. Radiology. 2019; 294(1):160-167. DOI: 10.1148/radiol.2019191140. View

5.
Hirschler L, Sollmann N, Schmitz-Abecassis B, Pinto J, Arzanforoosh F, Barkhof F . Advanced MR Techniques for Preoperative Glioma Characterization: Part 1. J Magn Reson Imaging. 2023; 57(6):1655-1675. PMC: 10946498. DOI: 10.1002/jmri.28662. View